Journal article
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
W Chua, D Goldstein, CK Lee, H Dhillon, M Michael, P Mitchell, SJ Clarke, B Iacopetta
British Journal of Cancer | Published : 2009
Abstract
Background:To investigate three genetic alterations (TP53 mutation, Kras mutation and microsatellite instability (MSI)) and three polymorphisms (methylene tetrahydrofolate reductase (MTHFR) C677T, excision repair cross complementing group 1 (ERCC1)-118 and X-ray repair cross complementing group 1 (XRCC1)-399) for their ability to predict response, survival and toxicity to FOLFOX first line chemotherapy in the treatment of metastatic colorectal cancer (mCRC).Methods:Tumour tissues from 118 mCRC patients who underwent FOLFOX treatment from three successive phase II trials were evaluated for mutations in TP53 (exons 5-8) and Kras (codons 12 and 13) and for MSI using PCR-based analysis. Genotypi..
View full abstractGrants
Funding Acknowledgements
We thank Sanofi-Aventis for provision of an unrestricted grant to support this study. Haryana Dhillon received a consulting contract from Sanofi-Aventis for tissue collection. No further financial disclosures. Dr Wei Chua was supported by a NSW Cancer Institute Clinical Fellowship.